Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.
暂无分享,去创建一个
G. Bonadonna | C. Brambilla | P. Valagussa | M. Zambetti | G Bonadonna | P Valagussa | C Brambilla | A Moliterni | M Zambetti | A. Moliterni
[1] D. Cox. Regression Models and Life-Tables , 1972 .
[2] G. Bonadonna,et al. Dose-response effect of adjuvant chemotherapy in breast cancer. , 1981, The New England journal of medicine.
[3] Anna L. Brown,et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Rupert G. Miller,et al. Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.
[5] G. Bonadonna,et al. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Peto,et al. Asymptotically Efficient Rank Invariant Test Procedures , 1972 .
[7] L. Norton,et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.
[8] G Marini,et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse , 1994, The Lancet.
[9] G. Bonadonna,et al. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.
[10] G. Bonadonna,et al. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] G. Bonadonna,et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.
[12] G. Bonadonna,et al. The CMF program for operable breast cancer with positive axillary nodes: Updated analysis on the disease‐free interval, site of relapse and drug tolerance , 1977, Cancer.
[13] S. Love,et al. Adjuvant systemic therapy for patients with node‐negative tumors , 1990, Cancer.
[14] R. Zucali,et al. Primary chemotherapy in surgically resectable breast cancer , 1995, CA: a cancer journal for clinicians.
[15] R. Gelber,et al. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] G. Bonadonna,et al. Salvage treatments in relapsing resectable breast cancer. , 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[17] C. Redmond,et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. , 1975, The New England journal of medicine.